Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05523947). This is a study registration, not published results. Lead sponsor: Yuhan Corporation. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 147 participants (ESTIMATED). Conditions: HER2-Positive Solid Tumor. Interventions: DRUG: YH32367. Primary outcome measures: Treatment-emergent adverse events (TEAEs) up to Day 21 , in dose escalation part, an average of 21 days; Objective Response Rate (ORR) , through dose expansion part completion, approximately 2.5 year. Brief summary: This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.